Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels.
about
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulationDabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional ExperienceNon-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused ReviewUncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis.A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation--full speed ahead or proceed with caution?Management of acute stroke in patients taking novel oral anticoagulants.Dabigatran: patient management in specific clinical settings.Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.Management of non-vitamin K antagonist oral anticoagulants in the perioperative settingA proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin timeCoagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatranMeasurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.Global assays and the management of oral anticoagulation.Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug ConcentrationsUPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays.Direct oral anticoagulant drug level testing in clinical practice: A single institution experience.Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTHPatient Taking A Novel Oral Anticoagulant Presents With Major GI Bleeding.Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation.Reversal of anticoagulant effects in patients with intracerebral hemorrhage.Management of peri-operative anti-thrombotic therapy.Practical issues in the management of novel oral anticoagulants-cardioversion and ablation.Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.Assessing nonvitamin K antagonist oral anticoagulants (NOACs) in the laboratory.Pearls and pitfalls in factor inhibitor assays.Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review.Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication.Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants.Laboratory measurement of the direct oral anticoagulants.Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives.The laboratory's 2015 perspective on direct oral anticoagulant testing.Dabigatran reduces thrombin-induced platelet aggregation and activation in a dose-dependent manner.Minimizing the Risk of Bleeding with NOACs in the Elderly.Novel oral anticoagulant management issues for the stroke clinician.Measurement and reversal of the direct oral anticoagulants.Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.New Oral Anticoagulants and Their Reversal Agents.Direct Oral Anticoagulants: An Overview for the Interventional Radiologist.The danger of relying on the APTT and PT in patients on DOAC therapy, a potential patient safety issue.
P2860
Q26749141-C3D30C37-3332-4290-9F31-2024FEFB4CABQ26783457-F728EFCE-306A-4336-AF47-3F315D000EF8Q28081918-6AAA79F0-C138-41B6-9DD5-6F3855CD53E7Q33631115-289EBAEA-DFA7-4545-AD49-A85CDCD6FDEEQ34109813-D944D0D5-C9DC-4020-8D0E-D93E18BBA3A0Q34111320-A12B55D5-D97E-47FB-B197-7A34ADC75E0EQ34196100-B5DB7DF8-346B-41A0-98A2-20B464AEA649Q34206252-2DB4E4A9-A63D-4BC5-8A16-2D25D82390E8Q34207558-A5A6A477-2222-4334-81A5-A9E1DBB17621Q34571082-15344B79-A4A5-487D-BA0D-0A2C9E2F0070Q34571099-4593B367-2886-4B4A-87A8-847757006F11Q35154142-A46E1B06-037F-46B7-9BD8-1FC539D61E15Q35164902-7F60E50A-2FA6-4AD8-83FF-AE32BE1DA7DEQ35674404-6EFC7F6E-A756-4560-B19C-3E6FBB557BB0Q35877331-109938F8-EC5E-4D22-803A-11E3165D673AQ37037385-07F469C3-6648-4A5B-9414-52B96CB25DF1Q37073792-86C2B5EB-FEAC-48A3-A91F-EA34BBE257DBQ37114565-DA21A9D6-A6B6-4A63-97C2-73BE1BB5C241Q38186641-C7002782-168B-41FF-AC68-B04E3583A2FCQ38262325-EB8A9F3F-D433-4AEA-ADA3-A2182DFA6F51Q38269290-5AF631CE-E0E2-4E02-9C2E-9C43C82DB21FQ38273789-311C561B-3685-4DB3-B319-D4393F7BD9B1Q38365022-7346AF07-E740-4F1D-BEE9-AEB2AFA9397FQ38380827-998A4759-1996-466E-BBBD-8F0D3F8035CFQ38481929-B01F3E1C-7831-46F0-B187-D0B64AE778E4Q38481939-05C84F30-435E-44A7-B373-DF1DFD89E2B5Q38566089-B7B75BA9-057F-472A-82A0-E780C2CF77A7Q38589753-660D2DA7-A768-4951-B67F-EB11E5A52AEEQ38608242-8E680556-18B7-4098-877B-F637D3319D28Q38613869-B7CE4B98-DDEF-49A6-88EE-EE19CBE7BC8CQ38620930-77BA1C7F-44CA-407A-986B-C7ED512E0D00Q38704892-5D2BEB6C-2F01-4A41-B861-E13A6CAA85F4Q38744436-83417D6E-1055-492F-A7E1-F80957A8FE4BQ38833382-4B47ACAC-F408-4DA8-87DD-6E2AF9642A1FQ38910667-308BEB21-CDD8-494F-9328-1EBB83128DDEQ38953781-B0D0B37C-9D55-45C8-BEE1-B682BFA44D6CQ38956699-D4BE50C9-C596-44FB-8EF0-9A462C735E4BQ38970532-B7C30C19-73FF-4B1B-98A4-3B66DC234275Q39028122-1E7FA189-8538-4CA3-87D1-8E2EC1D5FEABQ39266324-E6D18DB4-0520-426F-A2DB-CB655D770027
P2860
Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Performance of coagulation tes ...... peak and trough plasma levels.
@en
Performance of coagulation tes ...... peak and trough plasma levels.
@nl
type
label
Performance of coagulation tes ...... peak and trough plasma levels.
@en
Performance of coagulation tes ...... peak and trough plasma levels.
@nl
prefLabel
Performance of coagulation tes ...... peak and trough plasma levels.
@en
Performance of coagulation tes ...... peak and trough plasma levels.
@nl
P2093
P2860
P356
P1476
Performance of coagulation tes ...... peak and trough plasma levels.
@en
P2093
A M Winkler
C Jeanneret
D Funk-Adcock
H C Whinna
J M Taylor
R Gosselin
P2860
P304
P356
10.1111/JTH.12308
P577
2013-08-01T00:00:00Z